Errors in Results Section

In the Original Investigation titled “Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial,”¹ published in the September issue of JAMA Dermatology, all of the P values at week 24 in the last paragraph of the “Efficacy Outcomes” subsection of the Results section have now been included as a part of the primary output of the trial because they were part of the prespecified analyses, and the percentage of 205 of 344 dupilumab-treated patients should be 59.5%, not 59.2%. Also, more data were added to eTable 5 in Supplement 2. This article has been corrected online.